Data gathered: February 23
Alternative Data for CureVac
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 27 | Sign up | Sign up | Sign up |
| Sentiment | 33 | Sign up | Sign up | Sign up |
| Webpage traffic | 47,000 | Sign up | Sign up | Sign up |
| Employee Rating | 62 | Sign up | Sign up | Sign up |
| Google Trends | 23 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 2 | Sign up | Sign up | Sign up |
| Twitter Followers | 18,844 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 615 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 25 | Sign up | Sign up | Sign up |
| Linkedin Employees | 740 | Sign up | Sign up | Sign up |
About CureVac
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
| Price | $3.30 |
| Target Price | Sign up |
| Volume | 1,160,000 |
| Market Cap | $740M |
| Year Range | $2.49 - $4.68 |
| Dividend Yield | 0% |
| PE Ratio | 6.73 |
| Analyst Rating | 50% buy |
| Industry | Biotechnology |
In the news
CureVac: The mid-term effect of pipeline pruningFebruary 20 - Finnhub |
|
 |
CureVac (NASDAQ:CVAC) Earns “Market Outperform” Rating from JMP SecuritiesFebruary 16 - ETF Daily News |
$16.85 Bn Influenza Vaccines Market Research 2025-2033: Expansion of Production Capacity, Strategic Partnerships and Collaborations, Advancements in DevelopmentFebruary 11 - GlobeNewswire |
|
Epitopea Appoints Klaus Edvardsen M.D., Ph.D. as Chief Medical OfficerFebruary 7 - Financial Post |
|
 |
Stargate: Trump Partners with Technocrats to Promote mRNA Injections, AI, and TranshumanismJanuary 29 - Activistpost.com |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Read more about CureVac (CVAC) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, twitter followers, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of CureVac?
The Market Cap of CureVac is $740M.
What is CureVac's PE Ratio?
As of today, CureVac's PE (Price to Earnings) ratio is 6.73.
What is the current stock price of CureVac?
Currently, the price of one share of CureVac stock is $3.30.
How can I analyze the CVAC stock price chart for investment decisions?
The CVAC stock price chart above provides a comprehensive visual representation of CureVac's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling CureVac shares. Our platform offers an up-to-date CVAC stock price chart, along with technical data analysis and alternative data insights.
Does CVAC offer dividends to its shareholders?
As of our latest update, CureVac (CVAC) does not offer dividends to its shareholders. Investors interested in CureVac should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of CureVac?
Some of the similar stocks of CureVac are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.